Impact of UniversalHaemophilus influenzaeType b Vaccination Starting at 2 Months of Age in the United States: An Economic Analysis
- 1 October 2002
- journal article
- Published by American Academy of Pediatrics (AAP) in PEDIATRICS
- Vol. 110 (4), 653-661
- https://doi.org/10.1542/peds.110.4.653
Abstract
Objective. To evaluate the economic impact of universal Haemophilus influenzae type b (Hib) vaccination starting at 2 months of age.Methods. Decision-tree-based analysis was conducted of a hypothetical US birth cohort of 3 815 469 infants using population-based vaccination coverage and disease incidence data. All costs were estimated from both the direct cost (medical and nonmedical) and societal perspectives. Net present value, cost-effectiveness ratios, and benefit-cost ratios of the US Hib vaccination program were evaluated.Results. The results of these analyses showed that the universal vaccination program using the Hib conjugate vaccines in the United States in 2000 was cost-saving from both the direct and societal perspectives, with the benefit of the Hib vaccination program (net present value) from the direct cost and societal perspectives of $0.95 billion and $2.09 billion, respectively. Without a Hib vaccination program, the direct and societal costs of Hib invasive cases would be $1.35 billion and $2.58 billion, respectively. The direct and societal costs of the Hib vaccination program were estimated at $0.39 billion and $0.48 billion, respectively. The direct and societal benefit-cost ratios for the Hib vaccination program were 3.4 and 5.4, respectively. Varying the proportion of vaccines purchased and administered in the public versus the private sector and the proportion of combination vaccine versus monovalent vaccine administered did not have much effect on the results.Conclusions. Regardless of the perspective (direct cost or societal) and the assumptions used, the benefit-cost ratios of the US vaccination program are >1.0. Potential changes in the program, including use of more or less Hib combination vaccines, would not significantly alter the benefit-cost ratio. The national Hib vaccination program is highly cost beneficial and results in substantial cost savings.Keywords
This publication has 36 references indexed in Scilit:
- Cost of Illness of Epilepsy in the US: Comparison of Patient-Based and Population-Based EstimatesNeuroepidemiology, 2000
- Cost-effectiveness evaluation of vaccination against Haemophilus influenzae invasive diseases in FranceVaccine, 1996
- Economic aspects of a general vaccination against invasive disease caused by Haemophilus influenzae type b (Hib) via the experience of the Children's Hospital La Fe, Valencia, SpainVaccine, 1995
- Invasive Haemophilus influenzae Type b Disease in Children <5 Years of Age in Minnesota and in Dallas County, Texas, 1983-1984The Journal of Infectious Diseases, 1992
- InvasiveHaemophilus influenzaeinfections among children in Rochester, Minnesota: a population-based studyPaediatric and Perinatal Epidemiology, 1990
- Cost-benefit analysis of Haemophilus influenzae type b preventionThe Pediatric Infectious Disease Journal, 1990
- Primary invasive Haemophilus influenzae type b disease: A population-based assessment of risk factorsThe Journal of Pediatrics, 1986
- Risk factors for primary invasive Haemophilus influenzae disease: Increased risk from day care attendance and school-aged household membersThe Journal of Pediatrics, 1985
- Rifampin chemoprophylaxis for household contacts of patients with invasive infections due to Haemophilus influenzae type bThe Journal of Pediatrics, 1981
- Haemophilus influenzaeMeningitisThe New England Journal of Medicine, 1979